A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Enhertu is fast becoming a major growth product for Daiichi Sankyo and AZ ... Its fast growth comes on the back of a lengthening list of indications across breast, gastric, and non-small cell ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

Vanflyta was approved by the Medicines and Healthcare products Regulatory Agency ... NICE with a confidential discount on its list price, and Daiichi Sankyo UK's head of oncology, Haran Maheson ...

The approval was based on results from the TROPION-Breast01 Phase III trial.

Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review ...

The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). AstraZeneca and Daiichi Sankyo will continue ...

In a pooled analysis from two trials, Dato-DXd has shown promise as a treatment for advanced EGFR-mutated NSCLC.